Biodexa Pharmaceuticals (BDRX) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BDRX Stock Alerts $1.00 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBiodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meetingfinance.yahoo.com - April 30 at 12:01 PMBiodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meetingglobenewswire.com - April 30 at 11:52 AMWhy Is Biodexa (BDRX) Up 70% Today?investorplace.com - April 26 at 3:18 PMmarketbeat.com - April 26 at 9:38 AMBiodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)finance.yahoo.com - April 26 at 8:40 AMBiodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)globenewswire.com - April 26 at 8:30 AMPreliminary Results for the Year Ended 31 December 2023globenewswire.com - April 19 at 8:00 AM7 stocks to watch on Tuesday: CHX on SLB deal, managed care players and moremsn.com - April 3 at 4:52 AMView reaches deal with Cantor Fitzgerald and RXR to become a private companymsn.com - April 3 at 4:52 AMJob openings roughly flat in February, with prior month's print revised down - JOLTSseekingalpha.com - April 2 at 6:50 PMU.S. factory orders rise more than forecast in Februarymsn.com - April 2 at 6:50 PMBiodexa reports promising brain cancer drug resultsuk.investing.com - March 30 at 3:14 PMBiodexa Pharmaceuticals Plc: Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancersfinanznachrichten.de - March 28 at 1:31 PMGold Gains 1%; Walgreens Narrows Earnings Forecastbenzinga.com - March 28 at 1:31 PMUS Stocks Flat; Initial Jobless Claims Fall To 210,000msn.com - March 28 at 1:31 PMBiodexa Pharmaceuticals files to sell 1.28B shares for holdersmsn.com - March 18 at 5:56 PMEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flatmsn.com - March 1 at 12:39 PMBiodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Updatefinanznachrichten.de - February 23 at 10:49 AMBiodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Updateglobenewswire.com - February 23 at 8:30 AMBiodexa Pharmaceuticals PLC: Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patientsfinanznachrichten.de - February 9 at 7:46 AMBiodexa Pharmaceuticals PLC: Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024finanznachrichten.de - January 22 at 2:35 PMBiodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024finance.yahoo.com - January 22 at 9:35 AMBiodexa Pharmaceuticals Plc (BDRX)uk.finance.yahoo.com - December 25 at 1:40 PMBiodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Optionfinance.yahoo.com - December 21 at 4:13 PMWhy Biodexa Pharmaceuticals (BDRX) Shares Are Getting Hammeredmsn.com - December 19 at 12:32 PMEuropean Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Tradingmsn.com - December 11 at 12:33 PMEuropean Equities Traded in the US as American Depositary Receipts Flat in Thursday Tradingmsn.com - November 30 at 12:31 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesdaymsn.com - November 29 at 3:17 PMmarketbeat.com - November 28 at 3:48 PMmarketbeat.com - November 27 at 10:16 AMmarketbeat.com - November 27 at 9:53 AMmarketbeat.com - November 27 at 9:48 AMBiodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetesfinance.yahoo.com - November 27 at 9:47 AMmarketbeat.com - November 27 at 9:38 AMBiodexa Pharmaceuticals PLC: Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastomafinanznachrichten.de - October 3 at 1:16 PMBiodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)finance.yahoo.com - September 21 at 10:42 AMmarketbeat.com - August 31 at 2:41 PMmarketbeat.com - August 31 at 2:32 PMmarketbeat.com - August 31 at 2:18 PMmarketbeat.com - August 31 at 2:02 PMEuropean Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday's Sessionmsn.com - August 15 at 6:56 PMmarketbeat.com - August 8 at 9:57 AMmarketbeat.com - August 8 at 9:48 AMmarketbeat.com - August 4 at 12:26 PMmarketbeat.com - August 4 at 12:09 PMBiodexa Pharmaceuticals PLC: Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websitesfinanznachrichten.de - July 28 at 10:30 AMBiodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websitesfinance.yahoo.com - July 28 at 10:30 AMADRs End Mostly Higher; Steakholder Foods, Biodexa Pharmaceuticals Trade Activelymarketwatch.com - July 24 at 8:52 PMBiodexa Pharmaceuticals PLC: Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirementfinanznachrichten.de - July 24 at 3:52 PMmarketbeat.com - July 24 at 1:01 PM Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. BDRX Media Mentions By Week BDRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDRX News Sentiment▼0.000.36▲Average Medical News Sentiment BDRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDRX Articles This Week▼01▲BDRX Articles Average Week Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bio-Path News Today Qualigen Therapeutics News Today Clearmind Medicine News Today PainReform News Today Notable Labs News Today 180 Life Sciences News Today Galmed Pharmaceuticals News Today Dermata Therapeutics News Today CNS Pharmaceuticals News Today InMed Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDRX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.